详情页

当前位置：首页 > 详情页

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

6| 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]RemeGen Co., Ltd. [2]Oncology Hospital, Chinese Academy of Medical Sciences [3]Liaoning Tumor Hospital & Institute [4]Jilin University First Hospital [5]First Affiliated Hospital of China Medical University [6]Peking University People's Hospital [7]Zhejiang Cancer Hospital [8]Henan Cancer Hospital [9]Jiangsu Cancer Institute & Hospital [10]Jilin Provincial Tumor Hospital [11]Sun Yat-sen Memorial Hospital,Sun Yat-sen University [12]Sun Yat-sen University Cancer Prevention and Control Center [13]Guangdong Provincial People's Hospital [14]Qingdao University Hospital [15]Hunan Cancer Hospital [16]Anhui Provincial Hospital [17]The First Affiliated Hospital of Anhui Medical University [18]Anhui Provincial Cancer Hospital [19]Tianjin Cancer Hospital [20]The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine [21]Shandong Cancer Hospital [22]Qilu Hospital of Shandong University [23]West China Hospital [24]The Fourth Hospital of Hebei Medical University [25]Wuhan Union Hospital, China [26]Tongji Hospital [27]Hubei Cancer Hospital [28]First Affiliated Hospital of Zhejiang University School of Medicine [29]Cancer Hospital Affiliated to Guangxi Medical University [30]Chongqing University Cancer Hospital [31]Cancer Hospital of Guizhou Province [32]Shanxi Province Cancer Hospital [33]Bethune Hospital of Shanxi Province [34]Linyi Cancer Hospital [35]Yantai Yuhuangding Hospital [36]First Affiliated Hospital of Fujian Medical University [37]The First Affiliated Hospital of Xiamen University [38]Weihai Municipal Hospital [39]The Affiliated Hospital of Xuzhou Medical University [40]Xuzhou Central Hospital [41]Affiliated Hospital of Chengde Medical College [42]Affiliated Hospital of Hebei University [43]The First Affiliated Hospital of Xinxiang Medical College [44]Jinan Central Hospital [45]Zibo Central Hospital [46]Weifang People's Hospital [47]Neijiang Second People's Hospital

研究目的：

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ，previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.